Intravenous Delivery Articles & Analysis
10 news found
Bypassing the blood-brain barrier (BBB) and nose-to-brain delivery have long been the elusive “holy grail” for the treatment of CNS diseases. ...
Such SG EZ-be Pod is a small, wearable infusion device that can be programmed for a wide range of medications and delivery profiles, including at-home delivery. This subcutaneous drug delivery system is the flagship for Bexson’s proprietary ketamine formulation, BB106, and leverages Stevanato Group’s existing technology and broad ...
The paper titled, “ Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial ,” can be accessed here . ...
” Data to be presented at the ASGCT Annual Meeting include an oral presentation of a study looking at Sangamo’s innovative genetically engineered adeno-associated virus (AAV) capsid platform for delivery to the central nervous system (CNS) after cerebrospinal fluid administration. With protection from the blood-brain barrier, current gene delivery to ...
Key data from the first-in-human FORTITUDE trial shows that a single cycle of intravenous (IV) NG-350A drives dose-dependent increases in specific inflammatory biomarkers, consistent with the mechanism of the encoded anti- CD40 agonist. ...
” The study showed that when injected intravenously into mice with established human tumor xenografts, PsiOxus’ armed T-SIGn vectors reprogrammed the tumor microenvironment to a proinflammatory state. ...
NG- 641 is a systemically administered product that encodes for the tumor selective delivery of an anti-FAP/anti-CD3 bispecific, interferon alpha, CXCL9 and CXCL10. ...
Bexson Biomedical, Inc., a research-stage company developing a subcutaneous ketamine treatment platform for pain management and mental health disorders, announced today that they closed a $4.8 million Series A round of financing. Funding will support the company through pre-clinical and GMP manufacturing scale up for its proprietary ketamine formulation, BB106, and the development of a wearable ...
JCR has received an orphan drug designation for subcutaneous treatment of TEMCELL for EB, and are currently seeking a label extension for intravenous delivery of TEMCELL in Japan. There is no cure for EB in the current market, but MSC therapy using TEMCELL has shown promising signs in an investigator-initiated ...
ByIMAPAC
The Italian Biochemical Institute (IBI) “Lrenzini”, Comecer, and Particle Measuring Systems (PMS) recently partnered to leverage and combine the expertise of each entity to design a new drug delivery system and a filling line to safely and effectively manufacture it. ...